Clinical Trial

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 18, 2023 (before its estimated December 25, 2024 completion). Its status may not reflect the trial's current state.
Summary
This trial is a multicenter, prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of Penpulimab injection combined with cetuximab in the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-02-18; most recent amendment 2023-10-16.
Status change: Active, Not Recruiting → Recruiting 2023-09-11
Trial Details
NCT Number NCT05260671
Lead Sponsor Eye & ENT Hospital of Fudan University
Conditions Head and Neck Neoplasms, Recurrent Disease, Metastatic Cancer
Enrollment 48 participants
Start Date 2022-01-25
Primary Completion 2024-12-25 (estimated)
Study Completion 2026-12-25 (estimated)
Updated on ClinicalTrials.gov 2023-10-18